ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
CeloNova BioSciences Announces Positive Results From European Study Of Embozene(TM) Microspheres For Treatment Of Uterine Fibroids
CeloNova BioSciences, Inc.
("CeloNova"), leading and accelerating healthcare solutions through the
provision and development of innovative medical devices, has released data
from THE SPHERE, an 11 center, 8 country European study of uterine fibroid
embolization using the Company's Embozene(TM) Microspheres. The study
results were reported at the 20th Annual International Symposium on
Endovascular Therapy.
Patients in the study were followed for six months. According to one of
the Principal Investigators, Joachim Kettenbach, MD, Medical University of
Vienna, "Technical success was achieved in 98% of the patients. The side-
effects of fibroids such as pain and heavy menstrual bleeding were
significantly reduced while the patients' quality of life improved
substantially."
Embolization is a minimally invasive procedure for uterine fibroids
during which an Interventional Radiologist injects microspheres through a
tiny catheter to the site of the fibroid. The microspheres -- each about
the size of a period at the end of this sentence -- block the blood flow to
the fibroids causing them to atrophy. The procedure is an alternative for
most women with fibroids to surgical procedures such as hysterectomy or
myomectomy. Recovery time is measured in days rather than weeks.
CeloNova's Embozene(TM) Color-Advanced Microspheres are the only
microspheres that are color-coded by size. They have a hydrogel center and
an outer layer of the Company's proprietary coating, Polyzene(R)-F which
enhances biocompatibility.
"From the beginning, CeloNova has operated on the principle that our
products would give first-rate clinical outcomes for patients and meet the
real-world needs of physicians," said Thomas A. Gordy, President and Chief
Executive Officer. Gordy continued, "This study shows that Embozene(TM)
Microspheres embody that philosophy; reducing patients' symptoms while
improving their quality of life. Color-coding improves patient safety while
simplifying the job of those performing the procedure."
About CeloNova BioSciences, Inc.
Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences,
Inc., is a developer of novel medical devices based on the company's
patented Polyzene(R)-F surface coating technology. Polyzene(R)-F is highly
lubricious, anti-inflammatory, and bacterial-resistant making it an ideal
surface treatment for implanted medical devices. The company's current
product portfolio includes its Embozene(TM) Color-Advanced Microspheres and
the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other
innovative devices are currently in the company's developmental pipeline.
For more information, please visit http://www.celonova.com.
CeloNova BioSciences, Inc.
http://www.celonova.com
CeloNova Biosciences anunþã rezultate pozitive la Europene Studierea Embozene (TM) microsfere pentru tratamentul uterine Fibroids - CeloNova BioSciences Announces Positive Results From European Study Of Embozene(TM) Microspheres For Treatment Of Uterine Fibroids - articole medicale engleza - startsanatate